HALCINONIDE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for HALCINONIDE (HALCINONIDE).
Halcinonide is a corticosteroid that binds to glucocorticoid receptors, leading to increased synthesis of lipocortin (annexin-1), which inhibits phospholipase A2, reducing arachidonic acid release and subsequent prostaglandin and leukotriene synthesis. This results in anti-inflammatory, antipruritic, and vasoconstrictive effects.
| Metabolism | Halcinonide is metabolized primarily in the liver via conjugation and hydrolysis, though specific enzymes are not well delineated. It is excreted in urine and feces. |
| Excretion | Renal: ~50% as metabolites; biliary/fecal: ~40% as metabolites and unchanged drug. |
| Half-life | Terminal half-life: 4-6 hours; supports twice-daily topical dosing. |
| Protein binding | 99% bound to albumin and corticosteroid-binding globulin (CBG). |
| Volume of Distribution | 0.8 L/kg; indicates extensive tissue distribution. |
| Bioavailability | Topical: <1% (systemic); intralesional: near 100%. |
| Onset of Action | Topical: 2-3 hours; intralesional: immediate effect within minutes. |
| Duration of Action | Topical: 12-24 hours; intralesional: 7-10 days. |
| Molecular Weight | 454.5 |
Apply thin film topically to affected area 2 to 3 times daily.
| Dosage form | CREAM |
| Renal impairment | No dose adjustment required for topical use; systemic absorption is minimal. |
| Liver impairment | No dose adjustment required for topical use; systemic absorption is minimal. |
| Pediatric use | Apply thin film topically to affected area 2 times daily; use lowest effective dose for shortest duration; avoid prolonged use. |
| Geriatric use | Use with caution; apply thin film topically to affected area 2 times daily; avoid prolonged use due to increased risk of skin atrophy and systemic absorption. |
| 1st trimester | No adequate studies in pregnant women; potential fetal harm based on animal data; use only if potential benefit justifies risk. |
| 2nd trimester | Not recommended unless clearly needed; may cause fetal growth restriction, adrenal suppression. |
| 3rd trimester | Avoid use; prolonged use may cause neonatal adrenal suppression and hypoglycemia. |
Clinical note
Comprehensive clinical and safety monograph for HALCINONIDE (HALCINONIDE).
| Placental transfer | Crosses placenta; extent depends on potency, formulation, and application area; systemic absorption occurs with topical use. |
| Breastfeeding | Excreted in human milk in amounts that may be clinically significant; use with caution, especially with high doses or prolonged application on large areas. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to halcinonide or any component of the formulationUntreated bacterial, fungal, viral, or parasitic skin infectionsPerioral dermatitisRosaceaTopical application in external ear if tympanic membrane is perforated
| Precautions | Systemic absorption can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, hyperglycemia, and glycosuria., Use with caution in patients with impaired hepatic function., Prolonged use, use on large areas, occlusive dressings, or in children may increase systemic absorption., Local adverse effects include skin atrophy, striae, telangiectasias, burning, itching, irritation, dryness, folliculitis, hypertrichosis, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration, secondary infection, and miliaria., Avoid use on face, axillae, or groin unless directed by physician., Not for ophthalmic use., May mask signs of infection., Use in children: may cause HPA axis suppression and growth retardation more readily than adults. |
| Food/Dietary |
Loading safety data…
| Lactation Rating |
| L3 (Moderately Safe) |
| Teratogenic Risk | Topical corticosteroids are generally considered low risk for teratogenicity when used sparingly and for short durations. Animal studies have shown cleft palate and delayed ossification with high doses of systemic corticosteroids, but no adequate human studies exist for halcinonide. First trimester: Potential risk of oral clefts with systemic use; topical use likely minimal risk. Second/third trimesters: Risk of intrauterine growth restriction and adrenal suppression with prolonged systemic use; topical use minimal risk. |
| Fetal Monitoring | Monitor for signs of maternal hypothalamic-pituitary-adrenal (HPA) axis suppression with prolonged use over large areas or occluded sites. Fetal growth and amniotic fluid volume should be monitored if high-potency steroids used extensively in pregnancy. |
| Fertility Effects | No specific studies on halcinonide and human fertility. High-dose systemic corticosteroids may impair fertility (e.g., menstrual irregularities); topical halcinonide at recommended doses is unlikely to cause significant effects. |
| No known food interactions. However, avoid excessive alcohol consumption as it may worsen skin conditions and interfere with treatment. |
| Clinical Pearls | Halcinonide is a high-potency topical corticosteroid. Limit use to 2 consecutive weeks; avoid on face, groin, axillae, or under occlusive dressings due to increased systemic absorption. Monitor for local atrophy, telangiectasias, and striae. Taper discontinuation after prolonged use to avoid rebound. Not recommended in children under 12 due to higher systemic absorption risk. |
| Patient Advice | Apply a thin layer only to affected areas, usually twice daily. · Do not cover with bandages or plastic wrap unless directed by your doctor. · Avoid using on your face, armpits, or groin unless specifically instructed. · Wash hands after applying unless treating hands. · Do not use for longer than prescribed, typically no more than 2 weeks. · Report any signs of skin thinning, infection, or allergic reaction to your doctor. |